History
-
2020
06. GenePro SARS-CoV-2 Test Emergency Use Authorization from FDA
06. Listed on Kosdaq
-
2019
01. Winner of the 2019 Korean IP Awards
-
2018
04. Winner of the Prime minister citation of KOREA
07. New medical technology certificates from HIRA
(GenesWell ddEGFR Mutation Test)
-
2017
02. Commendation from ministry of food and drug safety (GenesWell BCT)
05. Register of genetic testing agency about prognostic diagnostics for Breast Cancer
09. Manufacturing & Product approval (Class III) GenesWell ddEGFR Mutation Test from MFDS
-
2016
08. GENCURIX-GenoBio Strategic partnership
09. Winner of Korean New Medicine Award 2016 (GenesWell ddEGFR Mutation Test)
11. Manufacturing & Product approval (Class III) for GenesWell BCT from MFDS
-
2015
07. Obtained GMP certificate
11. GENCURIX-KT(Korea Telecom) JV Establishment (NGeneBio)
-
2014
03. ISO13485 Certification
04. NET(New Excellent Technology) certificate for breast cancer multigene test
08. Selected for Ministry of Health and Welfare in Korea led Korea-Singapore international R&D collaborative research support project
-
2013
11. Selected by Ministry of Science, ICT, and Future Planning’s technology development business companion diagnostics business unit for its #1 main project
-
2012
03. Signed joint research and development agreement (Seoul National University College of Pharmacy Molecular pathology and cancer genome research lab)
07. GENCURIX established R&D Center affiliate
-
2011
09. Established GENECURIX
09. Signed Breast cancer prognosis diagnostic technology transfer agreement (Seoul National University College of Pharmacy Molecular pathology and cancer genome research lab)